GalNAc-Targeted C3 RNAi Agents for Durable Complement Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for complement-mediated renal diseases and paroxysmal nocturnal hemoglobinuria, such as IgA nephropathy and C3 glomerulopathy, lack effective, durable, and safe therapeutic options that can inhibit C3 gene expression proximally in the complement cascade, with existing therapies requiring frequent administration and having compliance issues.
Innovation Solution
Development of RNAi agents comprising modified sense and antisense strands, linked to a targeting ligand like N-acetyl-galactosamine, to inhibit C3 gene expression, which are administered less frequently and provide a suitable safety profile.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies (eculizumab, ravulizumab) are used to inhibit C5, then complement-mediated diseases are treated, but administration frequency is high (every 2 weeks to 2 months) and therapeutic effect is limited due to distal action in the cascade
Solution Approach 1:
The patent applies preliminary action by targeting C3 upstream in the complement cascade before C5 activation occurs. By inhibiting C3 conversion to C3b, the therapy prevents downstream complement activation including C5, achieving more complete blockade with potentially longer duration of action and reduced administration frequency compared to distal C5 inhibition.
Solution Approach 2:
The patent uses a novel conjugate structure as an intermediary, combining a C3-targeting RNAi agent with a transcytosis-mediated delivery system. This intermediary enables the therapy to cross biological barriers and achieve sustained C3 inhibition, improving both therapeutic effect and duration while reducing administration frequency.
2Reliability
If pegcetacoplan is used to inhibit C3, then proximal complement blockade is achieved, but administration is complex (subcutaneous infusion pump, 1 gram in 20 mL over one hour, twice weekly)
Solution Approach 1:
The patent replaces the mechanical infusion pump system with a simplified administration approach. The novel conjugate structure enables direct injection without requiring complex infusion equipment, significantly reducing administration complexity while maintaining proximal C3 blockade efficacy.
Solution Approach 2:
The patent changes the physical and chemical parameters of the C3 inhibition therapy by using a conjugate structure with optimized pharmacokinetic properties. This enables less frequent administration and simpler delivery methods while maintaining effective C3 blockade, improving ease of operation without sacrificing therapeutic reliability.
3Reliability
If existing C3 therapies are used, then complement activity is inhibited, but durability is insufficient requiring frequent administration and compliance issues arise
Solution Approach 1:
By targeting C3 upstream in the complement cascade, the patent achieves more complete and durable inhibition of complement-mediated pathology. This preliminary blockade prevents downstream activation events, extending therapeutic durability and reducing administration frequency compared to distal interventions.
Solution Approach 2:
The novel conjugate structure acts as an intermediary that enhances the durability of C3 inhibition. The transcytosis-mediated delivery system and optimized pharmacokinetic properties enable sustained therapeutic effect, improving compliance by reducing administration frequency while maintaining reliable complement inhibition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNAi agents effectively reduce C3 gene expression, offering a highly active and durable therapeutic option with improved safety and reduced administration frequency, addressing the limitations of existing treatments.
Implementation Method 1
RNAi agents for inhibiting expression of Complement Component C3 (C3)
Data Source
AI summary
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents or siRNAs, able to inhibit Complement Component C3 (C3) gene expression. Also disclosed are pharmaceutical compositions that include C3 RNAi agents and methods of use thereof. The C3 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosanine, to facilitate the delivery to hepatocyte cells. Delivery of the C3 RNAi agents in vivo provides for inhibition of C3 gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by C3 gene expression, including IgA nephropathy, C3 glomerulopathy, paroxysmal nocturnal hemoglobinuria, and/or other complement-mediated renal diseases.